Introduction
Giant cell arteritis (GCA) is a systemic immune-mediated vasculitis first described by Horton et al. [1] that affects medium-sized and large-sized arteries [2, 3] . The most commonly affected populations include Scandinavian and northern Europeans, more than 50 years age and women (two to six times more often than men) [4] . Concordance within monozygotic twins and familial clustering has also been reported [5, 6] . Overall GCA incidence is 15-25 per 100 000 per year in individuals more than 50 years, and the incidence increases with age to 44.7 per 100 000 per year among patients in at least ninth decade [6] [7] [8] . The most common symptom is headache, while perhaps the most specific is jaw claudication. Temporal artery biopsy (TAB) remains the gold standard for diagnosis, revealing inflammatory cell infiltration of arterial walls with or without giant cells and disruption of the internal elastic lamina leading to luminal occlusion and tissue ischemia. Preferential sites include main branches of the aorta, its primary and secondary branches including subclavian and axillary arteries, superficial temporal, ophthalmic, posterior ciliary, and vertebral arteries. Cranial nerves (e.g., optic nerves) and posterior cerebral circulation may be affected [3] . The aim of this review is to provide an update on GCA including clinical features, differential diagnosis, and treatment options.
Pathology
Despite recent advances in molecular medicine and immunology, the initial events that trigger the cascade of immune and inflammatory reactions responsible for GCA remains elusive [6] . Both adaptive and innate immune systems may play a role in GCA pathophysiology. The histopathologic hallmark of GCA is granulomatous inflammation surrounding the internal elastic lamina in medium and large vessels [3, 4] ; although the arterial media is most frequently affected, all three layers may be involved (Fig. 1) . Inflammatory infiltrate is composed of macrophages, lymphocytes, and fibroblasts. Multinucleated giant cells may or may not be present; one study found an association between the presence of giant cells and visual loss [9] . GCA might be a heterogeneous group of diseases differentiating according to the inflammatory cell components particularly the presence or absence of giant cells [9] . Varied temporal and spatial disease course may result in 'skip lesions': segments of uninvolved artery adjacent to areas of inflammation [10, 11] . Inflammation leads to local vascular damage and intimal hyperplasia potentially ending in stenosis and occlusion.
Clinical features
GCA has a wide spectrum of clinical manifestations related to both systemic inflammation and ischemia [12] . The most common presenting symptoms are headache, scalp tenderness, jaw claudication, and systemic manifestations (fever, weight loss, anorexia, and malaise) [13-15,16 ,17,18,19 ] . Clinical and laboratory features of GCA are as follows:
(1) The neuro-ophthalmological evaluation:
(a) headache, Polymyalgia rheumatica (PMR) is a closely related systemic inflammatory disease that may occur on a spectrum in the same population as GCA (40%) [3] . Characteristics of PMR include pain and morning stiffness in the neck, shoulder and pelvic girdles; however, PMR lacks ischemic manifestations and appears to respond to much lower doses of steroids [13, 15] . New-onset headache, change in prior headache are common presentations in two-third of patients with GCA [3] . Headache commonly affects temporal regions; however frontal, parietal or occipital areas may also be involved. Headache may be constant, intermittent, or may change characteristics over time with features that may mimic migraine, tension-type or cluster headache. Jaw claudication refers to ischemicrelated masseter pain provoked with mastication or speech and eased with rest; it is highly specific for GCA [6] . Scalp and direct temporal artery tenderness are also suggestive of GCA [15, 18, 20] . Subclavian and axillary arteries may be involved during the disease course (18%) [17] producing arm claudication, absent or asymmetrical pulses and blood pressure readings, peripheral paresthesias, or tissue gangrene [3] [4] [5] [6] . Aortic involvement particularly thoracic aorta may remain clinically silent or lead to arterial dilatation, aneurysm formation, and dissection at rates 17 times more than the normal population [17] . Early diagnosis of aortic involvement is mandatory to avoid vascular morbidity and mortality [17] . Neurological symptoms occur in approximately 30% of GCA patients, most commonly presenting as mononeuropathy or polyneuropathy (14%), or transient ischemic attack or stroke (3-4%) [3] . Alteration in mental status, memory dysfunction, depression, and dementia are less common symptoms [4, 6] . Ophthalmologic symptoms are common manifestations of GCA (14-70%) and may occur in isolation without other GCA symptoms (5-38%). Patients may present with monocular or binocular vision loss, diplopia, and ocular pain. Transient or permanent visual loss or diplopia in an elderly patient even in the absence of other systemic findings must raise the suspicion of GCA. Arteritic anterior ischemic optic neuropathy (AAION) is the most common ophthalmologic manifestation and typically presents with sudden, painless, and profound unilateral or bilateral vision loss (78-99%) [3] . Classic AAION finding include a pale 'chalky white' swollen optic nerve head eventually leading to atrophic cupped optic nerve head. Hemorrhages, cotton wool spots, and associated cilioretinal artery occlusion may also be observed (21%) [8] . Nonarteritic anterior ischemic optic neuropathy (NAION) is a separate entity that may be difficult to distinguish from AAION. NAION is typically unilateral, and acutely presents with hyperemic optic disc edema ultimately leading to segmental atrophy without clinically evident cupping of the optic nerve head. NAION is never preceded by transient visual loss or associated with cotton wool spots; these features should strongly raise suspicion for GCA. Central or branch retinal artery occlusion occurs less commonly than optic nerve involvement (10-13%); however, GCA must be considered in any elderly patients presenting with central retinal artery occlusion and no visible embolic material in the retinal arterioles. Diplopia may be an isolated finding or occurs in the setting of other GCA symptoms, and results from ischemia of extraocular muscles or ocular motor nerves (2-15%) [3] . The oculomotor nerve is the most commonly involved with the pupil often spared, although trochlear and abducens nerves may also be involved. The prognosis for GCArelated visual loss is usually poor, and some cases even exhibit short-term progression despite high-dose corticosteroids (27%); however, high-dose steroids are effective in reducing the likelihood of fellow eye involvement (54-95%) [3] .
Diagnosis
There are no specific clinical symptoms or novel laboratory markers for the definite diagnosis of GCA; however, the combination of clinic, laboratory tests, and histopathology comprise the diagnosis basics [15,16 ,18,19 ,20] . The American College of Rheumatology (ACR) criteria have a GCA diagnostic sensitivity of 93.5% and a specificity of 91.2%; however, important factors such as visual symptoms, jaw claudication, and C-reactive protein are not included. American College of Rheumatology 1990 Criteria for the classification of GCA are given below. Presence of three or more criteria is required for the diagnosis of GCA (reproduced with permission [18] ):
(1) age of onset greater than 50 years; (2) onset of new headache; (3) temporal artery abnormality (tender or reduced pulsation); (4) elevated erythrocyte sedimentation rate, defined as 50 mm/h using the Westergren method; (5) abnormal arterial biopsy -showing necrotizing vasculitis with predominant mononuclear cell infiltration or granulomatous inflammation.
The British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidelines included the following key features to aid early recognition:
(1) abrupt-onset headache (usually unilateral in the temporal area); (2) scalp tenderness; (3) jaw and tongue claudication; (4) visual symptoms (including diplopia); (5) constitutional symptoms; (6) polymyalgia symptoms; (7) limb claudication.
When a patient more than 50 years of age presents with the features discussed above, GCA should be considered (adapted with permission [18, 19 ] ). ESR is the most widely used laboratory test to support clinical suspicion.
The upper limit for normal ESR increases with age and has been defined as age divided by 2 for men, and age plus 10 divided by 2 for women. ESR may have prognostic value, with an increased risk of severe ocular complications in biopsy-proven GCA patients presenting with an ESR higher than 70 mm/h [21] . Prompt initiation of corticosteroid therapy and close follow-up of these patients is warranted to minimize the risk of irreversible vision loss [22 ] . Although a high ESR is a hallmark of GCA, it is a nonspecific indicator of inflammation and increases in malignancy, infection, connective tissue disorders, trauma, anemia, and hypercholesterolemia. While significant elevation of ESR is often present in GCA and it remains a useful aid to monitor disease activity, the ESR may be normal in up to 17% of GCA cases [3, 4, 6, 23] ; accordingly, a normal ESR cannot rule out GCA. CRP is an acute-phase protein released by liver hepatocytes in response to inflammation. CRP seems to be more sensitive (76-86%) than the ESR, and does not vary with age or sex. Diagnostic sensitivity increases to over 99% with combined use of ESR and CRP; however, use of CRP in disease monitoring is less documented [3, 4, 6] . Although most patients with GCA have both elevated ESR and CRP levels, the two tests can be discordant. Thrombocytosis is positively correlated with biopsy-proven GCA and remains an important marker in the diagnosis [3, 4, 6, 24] ; following corticosteroid treatment with corticosteroid, the platelet count promptly normalizes. Normocytic normochromic anemia is observed in 20-50% of GCA cases [25] . Temporal artery biopsy remains the gold standard diagnostic test. New onset headache, systemic symptoms (malaise, fever, weight loss, and anorexia), elevated acute phase reactants, or jaw claudication warrant a TAB. Because of skip lesions, a temporal artery specimen of at least 2 cm should be sought. If a TAB is negative and clinical suspicion remains high, biopsy on the contralateral side should be considered, providing a positive specimen in 4-15% of patients when the first biopsy is negative [26, 27] . Corticosteroid treatment should be started immediately in patients with suspected GCA; steroid therapy should not be withheld pending the TAB as histopathological findings persist for at least 2-6 weeks following steroid initiation [3] [4] [5] [6] [10] [11] [12] 28 ,29].
Imaging
Various imaging techniques have been recommended for diagnosis and follow-up of GCA and GCA-related complications. Ultrasound is a noninvasive technique to visualize affected arteries, evaluate changes in blood flow, and define arterial course before TAB. Arterial wall edema, appearing as hypo-echoic halos immediately adjacent to the arterial wall, has 69% sensitivity and 82% specificity to detect arterial edema [6, 20] . Fluorescein angiography (FA) is useful in selected cases, with findings to include prolonged choroidal and central retinal arterial filling times, and choroidal nonperfusion or filling defects [3, 6, 30] ; these findings have specificity as they are not present in NAION. Contrast-enhanced, high-resolution MRI allows noninvasive assessment of mural inflammation and thickening. Gadolinium contrast-enhanced imaging helps to diagnose large-vessel vasculitis and aortitis and can also be used to detect and grade the severity of GCA [3, 4, 6, 31] . T1-contrast spin echo MRI with high sub-millimeter spatial resolution can reliably assess vascular inflammatory changes of small superficial cranial arteries, and radial T2-weighted imaging may have the potential to detect inflammatory changes in the small superficial cranial arteries without the need for contrast [32] . Positron emission tomography (PET), MRI, and magnetic resonance imaging angiography may reveal extracranial involvement [18,33 ,34] .
Treatment
The goals of treatment are to halt progression of visual loss in the affected eye and prevent involvement of the fellow eye or other regions. Systemic corticosteroid therapy remains the mainstay of GCA treatment. Glucocorticoids exert multiple anti-inflammatory effects including suppression of monocytes/macrophages [35, 36] . There is still no consensus on the correct dose or route of administration of corticosteroids. Although treatment with intravenous methylprednisolone at least 1 g/day for a minimum of 3 days is employed in some clinics, other authors suggest oral prednisone 1 mg/kg [3, 6] . Some treatment response is usually evident within 24-72 h after initiation of therapy but complete normalization of ESR may take several weeks; however, in some cases, progression may occur despite early institution of high-dose corticosteroid treatment [4, 6] . It has been suggested that GCA patients with a strong initial systemic inflammatory reaction need higher and more prolonged corticosteroid requirements and experience more disease flares during corticosteroid therapy, although this is not a uniform finding [3, 37, 38] . Regardless of the initial starting dose, most patients remain on oral prednisone 1 mg/kg for a minimum of 4 weeks after which time steroids should be tapered on the basis of symptoms and serial monitoring of inflammatory markers. Rate of steroid taper is about 10 mg/month initially (or 10% of the total daily dose every 1-2 weeks) then decrease in 1-2.5 mg increments once a dose of 10-15 mg per day is reached [3, 35] . Most patients require treatment for a minimum of 1 year; however, lifelong treatment may be needed under certain circumstances. The frequency of adverse side effects with high-dose steroids is high and can cause important morbidity; most steroid side effects are dose related, so it is important that efforts are made to use the lowest doses for the shortest time possible [37] . Cytotoxic drugs including methotrexate (MTX) have been suggested as an adjuvant therapy; however, there have been conflicting results concerning the ability of this medication to provide steroid sparing effects [39] [40] [41] . Although azathioprine, cyclophosphamide, dapsone, and cyclosporine have been suggested as possible corticosteroid sparing agents, there are no conclusive studies regarding their usefulness in GCA [42] . Antitumor necrosis factor monoclonal antibody (e.g., Infliximab) has been proposed as either first-line therapy or a steroid-sparing agent in GCA; however, a randomized placebo-controlled multicentre trial on the efficacy and safety of infliximab showed no beneficial effects [3, 6, 43, 44] . Antiplatelet aggregation therapy with low-dose aspirin before or at the time of diagnosis has been associated with a lower risk for developing acute vision loss and cerebrovascular accidents [42, 44, 45] . A retrospective case series showed that patients receiving aspirin at the initial presentation were five times less likely to experience cranial ischemic complications [44] . We routinely employ high-dose corticosteroids, often via the IV route, in combination with antiplatelet agents in cases strongly suspected of GCA.
Conclusion
GCA is a systemic vasculitis with a wide spectrum of features that must be suspected in any patient over age of 50 presenting with otherwise unexplained visual symptoms, AAION, jaw claudication, elevated ESR or CRP. The diagnosis remains a challenge as up to 20% of patients with a positive temporal artery biopsy would not exhibit an elevated ESR or systemic symptoms. High-dose corticosteroids are the mainstay of GCA in order to prevent progression of symptoms. GCA-related mortality is highly associated with cardiovascular or neurological complications such as cerebral or myocardial infarction, congestive heart failure, and aortic aneurysm rupture/dissection [3] . Patients controlled with corticosteroids remain at risk for recurrent symptoms as steroid dose is tapered, most commonly in the first 18 months. Further research concerning immunogenetics and treatment trials are needed to develop more specific and sensitive diagnostic tests and new corticosteroid-sparing treatment modalities.
